Hansa Biopharma — November 2025
-
"In summary, we think the KOL event underlines the high unmet need that imlifidase satisfies and gives us stronger conviction in our sales forecast. We believe the market does not fully appreciate the high likelihood of approval (barring any CRL) and likely rapid uptake of imlifidase in the US, basing its expectations on the relatively unsuccessful European sales trajectory."
-
"relatively unsuccessful" er vist en meget pæn formulering
-
Optimistic Buy Rating for Hansa Biopharma AB: Imlifidase’s Potential in Kidney Transplantation Highlighted by Key Opinion Leaders
-
-
Shortede aktier i Hansa B. https://shortregister.com/se/hansa-biopharma-hnsa?utm_source=chatgpt.com
-
26/11 Leerink Partners Initiates Coverage of Hansa Biopharma with Outperform Rating, Target Price Set at SEK 102 - BN
https://www.marketscreener.com/news/leerink-partners-initiates-coverage-of-hansa-biopharma-with-outperform-rating-target-price-set-at-s-ce7d5ed2d180f020
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind